Keywords: Orexigen, Contrave, USA, FDA, Takeda, Obesity

Orexigen and FDA find way forward for obesity drug Contrave

Article | 21 September 2011

Print This

Shares of US drug developer Orexigen Therapeutics (Nasdaq: OREX) 86% to $2.74 in extended trading yesterday, after the company said that a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in